A Phase 2 interventional study of Venetoclax and Pomalidomide in Multiple Myeloma, sponsored by AbbVie. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.
Among the 20 studies testing venetoclax in Multiple Myeloma, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 10th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:
Oncotherapeutics · Sites in United States
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
University of Miami · Sites in United States
Ages 18+
Melbourne Health · Sites in Australia
Ages 18–75
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 3
First in 2012; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 42 across the 20 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 32nd largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2018, is one of 8 in phase 2, and was the 21st registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
4 of the studies testing venetoclax in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05391750Emory UniversityVenetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | 2027-02-12 |
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT02899052AbbVieStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing venetoclax in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participants were to be divided into 2 cohorts, participants positive for t(11;14) translocation and participants negative for t(11;14) translocation.
Following communication of the results of the primary progression-free survival (PFS) analysis from the Phase 3 BELLINI study (Study M14-031; NCT02755597), the company-sponsored MM studies were placed on partial clinical hold (PCH) in March 2019 by the United States (US) Food and Drug Administration and enrollment was halted. The sponsor did not pursue release of the PCH for this study; therefore, enrollment was not re-opened. In accordance with the terms of the PCH, participants who were deriving clinical benefit were allowed to continue to receive treatment. One participant was still active in Part 1 of the study when the sponsor decided not to pursue release of the PCH (in January 2020) and, therefore, continued to receive treatment and have regular assessments until disease progression. The study was discontinued when the last participant completed study treatment. No participants were enrolled in Part 2 of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venetoclax (400 mg oral \[PO\], once daily \[QD\]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly \[qw\]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone
Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])
Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone
Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])
Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone
Tablet; oral
Also known as: ABT-199, GDC-0199, Venclexta
Capsule; oral
Also known as: Pomalyst
Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks)
Overall Response Rate (ORR)
ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using the International Myeloma Working Group (IMWG) 2016 criteria for disease response and progression. CR= negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow; sCR= CR + normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow; VGPR= serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level + urine M-protein level \< 100 mg per 24 hours; PR= ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours.
Time frame: Approximately 15 months
Progression-Free Survival (PFS)
PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug.
Time frame: Approximately 20 months
Duration of Response (DOR)
DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response \[PR\] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.
Time frame: Approximately 15 months
Time-to-progression (TTP)
TTP for a given participant is defined as the number of days from the date of first dose to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.
Time frame: Approximately 15 months
| Milestone | All Participants |
|---|---|
| Started | 8 |
| Completed | 0 |
| Not completed | 8 |
| Withdrew: Disease progression | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 1 |
| Withdrew: Adverse event | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
| Participants | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation |
|---|---|---|
| Any TEAE | 3 | 5 |
| TESAE | 3 | 2 |
ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using the International Myeloma Working Group (IMWG) 2016 criteria for disease response and progression. CR= negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow; sCR= CR + normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow; VGPR= serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level + urine M-protein level \< 100 mg per 24 hours; PR= ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours.
| percentage of participants | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | All Participants |
|---|---|---|---|
| Overall Response Rate (ORR) | 66.7 (9.4 to 99.2) | 60.0 (14.7 to 94.7) | 62.5 (24.5 to 91.5) |
PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug.
| days | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | All Participants |
|---|---|---|---|
| Progression-Free Survival (PFS) | 220.0 (11.0 to NA) | NA (57.0 to NA) | 320.0 (11.0 to NA) |
DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response \[PR\] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.
| days | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | All Participants |
|---|---|---|---|
| Duration of Response (DOR) | 393.0 (NA to NA) | NA (NA to NA) | 393.0 (NA to NA) |
TTP for a given participant is defined as the number of days from the date of first dose to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.
| days | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | All Participants |
|---|---|---|---|
| Time-to-progression (TTP) | 420.0 (NA to NA) | NA (57.0 to NA) | 420.0 (57.0 to NA) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 70 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Positive for t(11;14) Translocation | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Participants Negative for t(11;14) Translocation | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Event | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation |
|---|---|---|
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 1/3 | 0/5 |
| PNEUMONIA STREPTOCOCCALInfections and infestations | 1/3 | 0/5 |
| BLOOD LACTATE DEHYDROGENASE INCREASEDInvestigations | 1/3 | 0/5 |
| PANCREATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/5 |
| CEREBRAL INFARCTIONNervous system disorders | 1/3 | 0/5 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 1/3 | 0/5 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/3 | 0/5 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/3 | 1/5 |
| PNEUMOCOCCAL INFECTIONInfections and infestations | 0/3 | 1/5 |
| PNEUMONIAInfections and infestations | 0/3 | 1/5 |
| Event | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation |
|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 2/3 | 4/5 |
| FATIGUEGeneral disorders | 2/3 | 2/5 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/3 | 1/5 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 2/3 | 0/5 |
| ANAEMIABlood and lymphatic system disorders | 1/3 | 3/5 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 0/3 | 3/5 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 1/3 | 3/5 |
| LEUKOPENIABlood and lymphatic system disorders | 1/3 | 2/5 |
| LYMPHOPENIABlood and lymphatic system disorders | 0/3 | 2/5 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/3 | 2/5 |
Full Analysis Set: participants who received at least 1 dose of study drug
| Age, Continuous(years) | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | Total |
|---|---|---|---|
| Median | 68.0 (67 to 74) | 66.0 (60 to 77) | 67.5 (60 to 77) |
| Sex: Female, Male(Participants) | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | Total |
|---|---|---|---|
| Female | 1 | 4 | 5 |
| Male | 2 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Participants Positive for t(11;14) Translocation | Participants Negative for t(11;14) Translocation | Total |
|---|---|---|---|
| White | 3 | 4 | 7 |
| Black/African American | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2018 to primary completion in Jun 2020, 20 months.
Results were first posted in Jun 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Pomalidomide · Dexamethasone